Tech Company Financing Transactions

Versartis Funding Round

Versartis secured a $21 million Series B funding round on 2/16/2011. Backers included New Leaf Venture Partners, Advent Venture Partners and Index Ventures.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

275 Shoreline Dr. 450
Mountain View, CA 94065
USA

Phone

650-963-8580

Website

www.versartis.com

Email Address

[email protected]

Overview

Versartis (NASDAQ: VSAR) is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis has licensed the rights to three products (VRS-826, VRS-859, and VRS-317) from Amunix.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Jay Shepard

        

Chief Financial Officer

Joshua Brumm

        

Chief Medical Officer

George Bright

        

VP - Bus. Development

Paul Westberg

        

VP - Manufacturing

Patrick Murphy

        

VP - Operations

Eric Humphriss

        

VP - Product Management

Rajendra Mohabir

        

Browse more venture capital transactions:

Prev: 2/16/2011: Doxo venture capital transaction
Next: 2/16/2011: ExaGrid Systems venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary